- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: Arcoxia® | MK 0663 | MK-0663 | MK0663
etoricoxib is an approved drug
Compound class: Synthetic organic
Comment: Etoricoxib is a selective COX-2 inhibitor, non-steroidal anti-inflammatory (NSAID) drug.
COVID-19: Etoricoxib offers potential to be repositioned to inhibit cytokine storm in COVID-19 patients .
Ligand Activity Visualisation Charts
These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖
View more information in the IUPHAR Pharmacology Education Project: etoricoxib
|No information available.|
|Summary of Clinical Use|
|Used in the treatment of rheumatoid arthritis, osteoarthritis, chronic lower back pain, ankylosing spondylitis, acute pain and gout. There is no information regarding approval for medicinal use of etoricoxib on the US FDA website. Individual national agencies may have granted marketing approval.|